Peptide · developed by Novo Nordisk
CagriSema is a combination of cagrilintide and semaglutide, administered subcutaneously. It is studied in type 2 diabetes, hypertension and obesity.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07919405 | Phase 3 | Hypertension | Not yet recruiting | NVO |
| NCT07282613 | Phase 3 | Diabetes Mellitus, Type 2 | Recruiting | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diabetes Mellitus, Type 2HypertensionObesity
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →